Products - Lung cancer | Topic

Showing 22 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
14 April 2027
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Technology for cancer case finding using primary care records
Status:
Awaiting development
Programme:
HealthTech guidance
Expected publication date:
TBC
ProKnow cloud-based system for radiotherapy data storage, communication and management
Status:
Awaiting development
Programme:
HealthTech guidance
Expected publication date:
TBC
Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Lung cancer Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 22 products

Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]

Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]

Technology for cancer case finding using primary care records

ProKnow cloud-based system for radiotherapy data storage, communication and management

Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]

Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]

Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]

Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]

Lung cancer Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 22 products

Status
1 selected